Freija Verdoodt1, Christian Dehlendorff2, Susanne K Kjaer1,3. 1. Virus, Lifestyle and Genes, Danish Cancer Society Research Center. 2. Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center. 3. Department of Gynaecology, Rigshospitalet, University of Copenhagen, Denmark.
Abstract
BACKGROUND: A reduced, 2-dose schedule of human papillomavirus (HPV) vaccination has been endorsed for preadolescent women on the basis of immunogenicity data from randomized trials, and limited data suggest that even 1 dose may provide sufficient protection. Surveillance of the impact of <3 vaccine doses on clinical endpoints in the targeted age group is warranted. METHODS: We conducted a nationwide cohort study of all women aged 17-25 years, living in Denmark between 2006 and 2016. From nationwide registries, we extracted individual-level data on vaccination with the quadrivalent HPV (qHPV) vaccine at 16 years or younger, number of doses administered, diagnoses of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) or grade 3 or worse (CIN3+), and potential confounders. Using Poisson regression, we estimated incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for CIN2+ and CIN3+, according to vaccination status. RESULTS: The cohort comprised 590 083 women, of which 215 309 (36%) women were vaccinated at ≤16 years, and among these, 40 742 (19%) received <3 vaccine doses. A total of 5561 women had a diagnosis of CIN3+. We found considerable vaccine effectiveness against CIN3+ after 1 (IRR, 0.38 [95% CI, .14-.98]), 2 (IRR, 0.38 [95% CI, .22-.66]), or 3 (IRR, 0.37 [95% CI, .30-.45]) vaccine doses, compared to unvaccinated women. Results were similar for CIN2+. CONCLUSIONS: We find substantial effectiveness of qHPV vaccination against high-grade cervical precancerous lesions, among women vaccinated with 1, 2, or 3 doses at ≤16 years of age. One-dose vaccination appeared to provide similar protection as 3-dose vaccination.
BACKGROUND: A reduced, 2-dose schedule of human papillomavirus (HPV) vaccination has been endorsed for preadolescent women on the basis of immunogenicity data from randomized trials, and limited data suggest that even 1 dose may provide sufficient protection. Surveillance of the impact of <3 vaccine doses on clinical endpoints in the targeted age group is warranted. METHODS: We conducted a nationwide cohort study of all women aged 17-25 years, living in Denmark between 2006 and 2016. From nationwide registries, we extracted individual-level data on vaccination with the quadrivalent HPV (qHPV) vaccine at 16 years or younger, number of doses administered, diagnoses of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) or grade 3 or worse (CIN3+), and potential confounders. Using Poisson regression, we estimated incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for CIN2+ and CIN3+, according to vaccination status. RESULTS: The cohort comprised 590 083 women, of which 215 309 (36%) women were vaccinated at ≤16 years, and among these, 40 742 (19%) received <3 vaccine doses. A total of 5561 women had a diagnosis of CIN3+. We found considerable vaccine effectiveness against CIN3+ after 1 (IRR, 0.38 [95% CI, .14-.98]), 2 (IRR, 0.38 [95% CI, .22-.66]), or 3 (IRR, 0.37 [95% CI, .30-.45]) vaccine doses, compared to unvaccinated women. Results were similar for CIN2+. CONCLUSIONS: We find substantial effectiveness of qHPV vaccination against high-grade cervical precancerous lesions, among women vaccinated with 1, 2, or 3 doses at ≤16 years of age. One-dose vaccination appeared to provide similar protection as 3-dose vaccination.
Authors: Michelle L Johnson Jones; Julia Warner Gargano; Melissa Powell; Ina U Park; Linda M Niccolai; Nancy M Bennett; Marie R Griffin; Troy Querec; Elizabeth R Unger; Lauri E Markowitz Journal: Am J Epidemiol Date: 2020-04-02 Impact factor: 4.897
Authors: Julia Ml Brotherton; Alison Budd; Christopher Rompotis; Natasha Bartlett; Michael J Malloy; Rachael L Andersen; Kim Ar Coulter; Peter W Couvee; Nerida Steel; Gail H Ward; Marion Saville Journal: Papillomavirus Res Date: 2019-07-15
Authors: Aruna Kamineni; Paula R Blasi; Gabrielle D Gundersen; Malia Oliver; John B Dunn; Denise A Galloway; Margaret M Madeleine Journal: Infect Dis (Auckl) Date: 2021-05-20
Authors: Joske Hoes; Audrey J King; Tessa M Schurink Van't Klooster; Johannes Berkhof; Johannes A Bogaards; Hester E de Melker Journal: J Infect Dis Date: 2022-09-04 Impact factor: 7.759